| Original language | English |
|---|---|
| Pages (from-to) | 320-348 |
| Number of pages | 29 |
| Journal | Gastroenterology |
| Volume | 157 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Aug 2019 |
| Externally published | Yes |
ASJC Scopus Subject Areas
- Hepatology
- Gastroenterology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Gastroenterology, Vol. 157, No. 2, 08.2019, p. 320-348.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease
AU - Mack, David R.
AU - Benchimol, Eric I.
AU - Critch, Jeff
AU - deBruyn, Jennifer
AU - Tse, Frances
AU - Moayyedi, Paul
AU - Church, P.
AU - Deslandres, Colette
AU - El-Matary, Wael
AU - Huynh, Hien
AU - Jantchou, Prévost
AU - Lawrence, S.
AU - Otley, Anthony
AU - Sherlock, Mary
AU - Walters, Thomas
AU - Kappelman, Michael D.
AU - Sadowski, Dan
AU - Marshall, John K.
AU - Griffiths, Anne
N1 - Funding Information: The consensus group would like to thank Paul Sinclair and Karen Sparkes (Canadian Association of Gastroenterology representatives) for administrative and technical support and logistical assistance, and Pauline Lavigne and Steven Portelance (unaffiliated) for medical writing services, supported by funds from the Canadian Association of Gastroenterology. Author contributions: All authors contributed to the developing the recommendations, and crafting the manuscript. Funding Information: Funding This guideline was supported through unrestricted grants to the Canadian Association of Gastroenterology by AbbVie and Takeda Canada, which had no involvement in any aspect of the guideline development or manuscript preparation. In addition, this guideline was supported by a Planning and Dissemination Grant from the Canadian Institutes of Health Research Institute of Nutrition, Metabolism and Diabetes. EIB was supported by a New Investigator Award from the Canadian Institutes of Health Research, Crohn's and Colitis Canada, and the Canadian Association of Gastroenterology. EIB was also supported by a Career Development Award and the Career Enhancement Program from the Canadian Child Health Clinician Scientist Program. Conflicts of interest These authors disclose the following: EIB participated in an advisory board for AbbVie but did not receive compensation for participation, financial or otherwise. JC has served on advisory boards for Janssen, and consulted for Nestle Health Sciences. JD has served on advisory boards for AbbVie and Janssen, received research support from Janssen, and participated in speaker's bureaus for AbbVie and Janssen. PM has served on advisory boards for Allergan and Shire, received research support from Takeda, and participated in speaker's bureaus for AbbVie and Allergan. PC has served on advisory boards for Janssen, and participated in speaker's bureaus for AbbVie and Janssen. CD has served on advisory boards for AbbVie and Janssen and has participated as a speaker/moderator for both companies, though not part of a speaker's bureau. WE has served on advisory boards for AbbVie and Janssen, and received research support from Janssen. HH has served on advisory boards for AbbVie and Janssen, and received research support from AbbVie, Allergan, and Janssen. PJ has served on advisory boards for Ferring. AO has served on advisory boards for AbbVie and Janssen, and received research support from AbbVie, Astellas, Janssen, and Shire. MS has served on advisory boards for AbbVie and Janssen. TW has served on advisory boards for AbbVie and Janssen, received research support from AbbVie, and participated in speaker's bureaus for AbbVie, Janssen, and Nestle Health Sciences. MK has consulted for AbbVie, GlaxoSmithKline, and Janssen, received research support from AbbVie and Janssen, participated in speaker's bureaus for AbbVie, and has owned stock in GlaxoSmithKline and Janssen. JM has served on advisory boards for AbbVie, Allergan, AstraZeneca, Boehringer-Ingelheim, Celgene, Celltrion, Ferring, Hospira, Janssen, Merck, Proctor & Gamble, Pfizer, Pharmascience, Shire, and Takeda, and participated in speaker's bureaus for AbbVie, Allergan, Ferring, Janssen, Proctor & Gamble, Shire, and Takeda. AG has served on advisory boards for AbbVie, Janssen, Celgene, Ferring, Pfizer, Gilead, and Lilly, received research support from AbbVie, and participated in speaker's bureaus for AbbVie and Janssen. The remaining authors disclose no conflicts. Funding This guideline was supported through unrestricted grants to the Canadian Association of Gastroenterology by AbbVie and Takeda Canada, which had no involvement in any aspect of the guideline development or manuscript preparation. In addition, this guideline was supported by a Planning and Dissemination Grant from the Canadian Institutes of Health Research Institute of Nutrition, Metabolism and Diabetes. EIB was supported by a New Investigator Award from the Canadian Institutes of Health Research, Crohn's and Colitis Canada, and the Canadian Association of Gastroenterology. EIB was also supported by a Career Development Award and the Career Enhancement Program from the Canadian Child Health Clinician Scientist Program. The consensus group would like to thank Paul Sinclair and Karen Sparkes (Canadian Association of Gastroenterology representatives) for administrative and technical support and logistical assistance, and Pauline Lavigne and Steven Portelance (unaffiliated) for medical writing services, supported by funds from the Canadian Association of Gastroenterology. Author contributions: All authors contributed to the developing the recommendations, and crafting the manuscript. Conflicts of interest These authors disclose the following: EIB participated in an advisory board for AbbVie but did not receive compensation for participation, financial or otherwise. JC has served on advisory boards for Janssen, and consulted for Nestle Health Sciences. JD has served on advisory boards for AbbVie and Janssen, received research support from Janssen, and participated in speaker's bureaus for AbbVie and Janssen. PM has served on advisory boards for Allergan and Shire, received research support from Takeda, and participated in speaker's bureaus for AbbVie and Allergan. PC has served on advisory boards for Janssen, and participated in speaker's bureaus for AbbVie and Janssen. CD has served on advisory boards for AbbVie and Janssen and has participated as a speaker/moderator for both companies, though not part of a speaker's bureau. WE has served on advisory boards for AbbVie and Janssen, and received research support from Janssen. HH has served on advisory boards for AbbVie and Janssen, and received research support from AbbVie, Allergan, and Janssen. PJ has served on advisory boards for Ferring. AO has served on advisory boards for AbbVie and Janssen, and received research support from AbbVie, Astellas, Janssen, and Shire. MS has served on advisory boards for AbbVie and Janssen. TW has served on advisory boards for AbbVie and Janssen, received research support from AbbVie, and participated in speaker's bureaus for AbbVie, Janssen, and Nestle Health Sciences. MK has consulted for AbbVie, GlaxoSmithKline, and Janssen, received research support from AbbVie and Janssen, participated in speaker's bureaus for AbbVie, and has owned stock in GlaxoSmithKline and Janssen. JM has served on advisory boards for AbbVie, Allergan, AstraZeneca, Boehringer-Ingelheim, Celgene, Celltrion, Ferring, Hospira, Janssen, Merck, Proctor & Gamble, Pfizer, Pharmascience, Shire, and Takeda, and participated in speaker's bureaus for AbbVie, Allergan, Ferring, Janssen, Proctor & Gamble, Shire, and Takeda. AG has served on advisory boards for AbbVie, Janssen, Celgene, Ferring, Pfizer, Gilead, and Lilly, received research support from AbbVie, and participated in speaker's bureaus for AbbVie and Janssen. The remaining authors disclose no conflicts. Funding This guideline was supported through unrestricted grants to the Canadian Association of Gastroenterology by AbbVie and Takeda Canada, which had no involvement in any aspect of the guideline development or manuscript preparation. In addition, this guideline was supported by a Planning and Dissemination Grant from the Canadian Institutes of Health Research Institute of Nutrition, Metabolism and Diabetes. EIB was supported by a New Investigator Award from the Canadian Institutes of Health Research, Crohn's and Colitis Canada, and the Canadian Association of Gastroenterology. EIB was also supported by a Career Development Award and the Career Enhancement Program from the Canadian Child Health Clinician Scientist Program. Funding Information: Funding for the consensus meeting was provided by unrestricted, arms-length grants to the CAG by AbbVie and Takeda Canada, and a Planning and Dissemination Grant from the Canadian Institutes of Health Research. The CAG administered all aspects of the meeting, and the funding sources had no involvement in the process at any point, nor were they made aware of any part of the process from development of search strings and statements to drafting and approval of these guidelines. Funding Information: Funding This guideline was supported through unrestricted grants to the Canadian Association of Gastroenterology by AbbVie and Takeda Canada , which had no involvement in any aspect of the guideline development or manuscript preparation. In addition, this guideline was supported by a Planning and Dissemination Grant from the Canadian Institutes of Health Research Institute of Nutrition, Metabolism and Diabetes . EIB was supported by a New Investigator Award from the Canadian Institutes of Health Research , Crohn’s and Colitis Canada, and the Canadian Association of Gastroenterology . EIB was also supported by a Career Development Award and the Career Enhancement Program from the Canadian Child Health Clinician Scientist Program . Publisher Copyright: © 2019 AGA Institute and the Canadian Association of Gastroenterology
PY - 2019/8
Y1 - 2019/8
UR - http://www.scopus.com/inward/record.url?scp=85065548197&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065548197&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2019.03.022
DO - 10.1053/j.gastro.2019.03.022
M3 - Article
C2 - 31320109
AN - SCOPUS:85065548197
SN - 0016-5085
VL - 157
SP - 320
EP - 348
JO - Gastroenterology
JF - Gastroenterology
IS - 2
ER -